PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Similar documents
PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA First Exam. Fall 2004

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA First Exam Fall 2003

PHA Final Exam Fall 2006

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA First Exam Fall 2013

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Spring First Exam. 8 Aminoglycosides (5 points)

PHA5128 Dose Optimization II Case Study I Spring 2013

PHA Final Exam Fall 2001

Renal Function. 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular reabsorption 4. Excretion

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Name: UFID: PHA Exam 2. Spring 2013

General Principles of Pharmacology and Toxicology

TDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.

PHA 5128 Spring 2000 Final Exam

PHA 5128 Spring 2009 First Exam (Version B)

TDM. Measurement techniques used to determine cyclosporine level include:

TDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages

One-Compartment Open Model: Intravenous Bolus Administration:

Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University

Basic Concepts in Pharmacokinetics. Leon Aarons Manchester Pharmacy School University of Manchester

BASIC PHARMACOKINETICS

General Principles of Pharmacology and Toxicology

Renal Excretion of Drugs

Section 5.2: Pharmacokinetic properties

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

PHARMACOKINETICS SMALL GROUP II:

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

LD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

PHARMACOKINETICS SMALL GROUP I:

TDM of Aminoglycoside Antibiotics

Pharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist

Applied Biopharmaceutics & Pharmacokinetics Sixth Edition

Filtration and Reabsorption Amount Filter/d

BIOPHARMACEUTICS and CLINICAL PHARMACY

Renal Impairment From Dettli to Guideline: What can we learn?

Thus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.

Pharmacokinetic Modeling & Simulation in Discovery and non-clinical Development

Pharmacokinetics of Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Problem Set for Fundamentals 9 Oct 2013

Practical issues - dosing on extracorporeal circuits

ADME Review. Dr. Joe Ritter Associate Professor of Pharmacology

Effects of Liver Disease on Pharmacokinetics

ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO

The ADME properties of most drugs strongly depends on the ability of the drug to pass through membranes via simple diffusion.

Determination of bioavailability

Pharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core

Excretion of Drugs. Prof. Hanan Hagar Pharmacology Unit Medical College

PHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

we usually use PAH - a substance called para-amino-hippouric acid to measure Clearance because it has the following characteristics :

PHAR 7632 Chapter 16

Osnove farmakokinetike. Aleš Mrhar. Prirejeno po. A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne,

Acknowledgements. National Kidney Foundation of Connecticut Mark Perazella. Co-PI Slowing the progression of chronic kidney disease to ESRD

Renal Physiology. April, J. Mohan, PhD. Lecturer, Physiology Unit, Faculty of Medical Sciences, U.W.I., St Augustine.

Drug elimination and Hepatic clearance Chapter 6

Pharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen

Click to edit Master title style

Assem Al Refaei. Sameer Emeish. Dr.Alia. Hodaifa Ababneh & Abdullah Shurafa

The kidney. (Pseudo) Practical questions. The kidneys are all about keeping the body s homeostasis. for questions Ella

. Although there is a little

Physiology questions review

ICU Volume 11 - Issue 3 - Autumn Series

Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 4, 2010 National

Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 29, 2015 National

Pharmacokinetics I. Dr. M.Mothilal Assistant professor

INTRODUCTION TO PHARMACOKINETICS

BIOL 2402 Renal Function

Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment

It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.

TDM. Generally, hepatic clearance is determined by three main factors: These three factors can be employed in the following equation:

Terminology. Terminology. Terminology. Molarity number of moles of solute / Liter of solution. a) Terminology b) Body Fluid Compartments

AXITAB-CV TAB. COMPOSITION :

Lecture-2 Review of the previous lecture:

PHARMONITOR II. Optimisation of aminoglycosides dosage regimen with pharmacokinetics modeling. Pierre Wallemacq

Public Assessment Report. EU worksharing project paediatric data. Valcyte. Valganciclovir

Doses Target Concentration Intervention

PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007

Renal Clearance. Dr. Eman El Eter

Metformin Associated Lactic Acidosis. Jun-Ki Park 9/6/11

Based on the information in the official labeling, please answer the following:

Chapter 12 DRUG THERAPY 2001 Dennis A. Noe

Understand the physiological determinants of extent and rate of absorption

Clearance and Reabsorption. Use the following data to answer these questions. a. plasma flow rate in the afferent arterioles:

MODULE 8: URINALYSIS AND ACID BASE BALANCE

Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017

We will begin momentarily at 2pm ET. Slides available now! Recordings will be available to ACS members after one week.

Renal Disease and PK/PD. Anjay Rastogi MD PhD Division of Nephrology

Introduction to Clinical Diagnosis Nephrology

Pharmacokinetics. Karim Rafaat

Pharmacokinetics One- compartment Open Model Lec:2

Have you seen a patient like Elaine *?

Transcription:

PHA 5127 Second Exam Fall 2010 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1

Question Set I (True or False) (15 points) True (A) or False (B). On the bubble sheet mark A for true or B for false Mark whether the following statements are true (A) or false (B). Mark false if there is not sufficient information given to provide answer. Increases and Decreases, Differences should be of clinical significance, otherwise state F. The lipophilic drug A (neither an acid nor a base) is cleared only by hepatic metabolism, crosses membranes quite easily, dissolves in the GI tract. When given to Patient A, it has a fu of 0.1, a f ut of 0.3 and an intrinsic clearance of 3000 L/h. Patient B shows a tissue protein binding of 80%; the only difference to Patient A. 1: T F The oral bioavailability of this drug is high (>80%). 2: T F Changes in plasma protein binding will affect the AUC of this drug when given as an iv bolus to Patient A and B. 3: T F Patient B s clearance will differ from that of patient A. 4: T F Increase in tissue binding will affect the half life of the drug. 5: T F Increase in fu will affect the half life of the drug. 2

Question Set II Consider a hydrophilic unionized drug, eliminated only through renal elimination. How will an increase in both tissue binding (50% increase) and a change in creatinine clearance (50% increase) affect the initial concentration (C 0 ), clearance (CL), AUC, and half-life (t 1/2 ) when given as an iv bolus, bioavailability (F) when given as tablet of a low-extraction drug? (Please note that means no clinically relevant change, and clinically relevant changes) A: C 0, CL, F, AUC, t 1/2 B: C 0, CL, F, AUC, t 1/2 C: C 0, CL, F, AUC, t 1/2 D: C 0, CL, F, AUC, t 1/2 E: none of above combinations. 3

Question Set III (Matching) (20 points) For the physiological changes listed below, select the induced changes on the pharmacokinetic parameters for a lipophilic, protein bound acidic drug (pka=13.8) that is only eliminated through renal elimination. Some answers may be used more than once. However, only one answer per physiological change Select the clinically relevant effect on pharmacokinetic parameters (A) Cl (B) Cl (C) V D (D) F (E) nothing happens or effect is not listed Physiological change 12: Decrease in plasma protein binding 13: Increase in tissue binding 14: ph adjustment of urine from 7.4 to 6.3 15: Increase in GFR 4

Question set IV (20point) A drug (not an acid, not a base) is cleared through renal clearance (Cl ren =1 ml/min;), only. Plasma protein binding suddenly doubles. Indicate for this situation whether the following parameters increase (A), decrease (B), stay about the same (C) or not sufficient information is provided (D). 16: volume of distribution 17: oral bioavailability 18: renal clearance 19: k e, 5

Question Set V (20 points) The following drugs have been given at toxic doses. What methods could be used to treat the patient if: 20) Drug is eliminated mainly through hepatic metabolism (high extraction drug) 21) Drug is eliminated mainly through hepatic metabolism (low extraction drug) 22) Lipohilic, neutral drug (not an acid, not a base) is eliminated through kidney. 23) Lipophilic base, pk a = 11, is eliminated solely through the kidney. 24) Lipophilic base, pk a =7.4, eliminated solely through the kidney. Select for above drugs (the best single choice from the list below): A: Adjust urine ph B: Increase urine flow C: Give drug that induces liver enzymes D: Perform dialysis, as nothing else will work. E: It is worthwhile to check whether the drug is actively reabsorbed. If yes transporters could be blocked 6

25: A new hydrophilic drug is eliminated through renal and hepatic processes. Plasma protein binding is 50%. Urine flow is 2 ml. GFR is 120 ml/min. Liver blood flow is 60 L/h. E is 0.026, due to first pass metabolism in the liver. What value best describes the total clearance? You might have to round. (15 points) A: 15 ml/min B: 20 ml/min C: 25 ml/min D: 30 ml/min E: none of the above 7

Question Set VI (15 points) 29 Robert is very sick and needs treatment with an aminoglycoside. In order to start him on the aminoglycoside you have to estimate Robert s creatinine clearance. Robert is 5 ft 10 inches tall, 34 years old, male, and weights 140 kg. His serum creatinine is 1.5 mg/dl. What is Robert s creatinine clearance? You might have to round. A B C D E 60 ml/min 80 ml/min 100 ml/min 120 ml/min 140 ml/min 8

Question Set VII (30 points) A lipophilic drug A cleared only through liver metabolism was administered to two patients 1 and 2. The values of some of the physiological parameters of the two patients (fu Fraction unbound in plasma; fu,t Fraction unbound in tissue; Cll i Intrinsic Clearance ; Q Liver blood flow; Vp Plasma Volume; V tw Tissue Water volume) are given in the table along with the observed plasma concentration time profiles. Based on the information given in the table and the figure, answer whether the statement is true (A) or false (B). Parameters Patient 1 Dose(mg) 20 fu 0.6 fu,t 0.1 Cl i (L/hr) 30000 Q (L/hr) 90 V p (L) 5 V tw (L) 35 Patient 2 20 0.3 0.1 30000 90 5 35 30) T F Drug A is a low extraction drug? 31) 32) 33) T T T F The clearancee of the drug in patient 2 is higher than that in patient 1? F The Extraction ratio of the drug in patient 1 is twice that in patient 2? F The AUC of patient 2 is greater than that of the patient 1? 34) T F Oral bioavailability of patient 1 is more pronounced. 35) T F The Volume of distribution in patient 1 is higher to that in patient 2? 9

Question Set VIII (True or False) (15 points) True (A) or False (B). On the bubble sheet mark A for true or B for false Mark whether the following statements are true (A) or False (B) for a drug given as iv bolus when the concentration time profile is described by C=Cp o *e ke*t 27: T F It is assumed that membranes do not represent significant barriers. 28: T F The elimination rate depends on plasma concentration. 29: T F Drug metabolism is not saturable at doses used. 30: T F Renal transporters are not saturable at doses used. 31: T F Volume of Distribution depends on plasma concentration. 10

Question Set IX (15 points) True (A) or False (B). On the bubble sheet mark A for true or B for false Patient A receives 100 mg of drug A. Patient B 200 mg of drug B. Evaluate the following statements. (Assume IV-bolus administration and linear pharmacokinetics). 32: T F C o in patient A will be 100 mg. 33: T F At any given time after injection, the elimination rate in patient B will be twice that of patient A as high for 34: T F If patient B received 400 mg of drug B instead of 200 mg, the volume of distribution of patient A is likely to be twice as high. 11

Question Set X (15 points) 35. Select the diagram(s) that clearly show non linear pharmacokinetics with respect to clearancee and/or volume of distribution? A): 5, 9 B) 3, 8 C) 3, 4, 6 D) 3, 4, 5, 6, 9 E) 1, 2, 4 12

Question Set XI (10 points) 36. The pharmacokinetics of 4 new drugs (nothing is known about the acid/base character degree of ionization) were measured first time in man. Consider liver blood flow of 80 L/h, creatinine clearance of 120 ml/min, kidney blood flow 1.1 L/h, urine flow 1.5 ml/min. Oral bioavailability is determined by hepatic first pass metabolism. Clearance mechanism of the drugs is not known (Assume clearance is due to hepatic and/or renal processes) The following results were obtained: A) Drug A fu=0.5, Cl tot 1.1 L/h, oral bioavailability 100% B) Drug B fu=0.5 Cl tot 1.1 L/h, oral bioavailability 1% C) Drug C fu=0.5, Cl tot 0.75 ml/min, oral bioavailability 100% D) Drug D fu=0.5 Cl tot, 60 ml/min, oral bioavailability 100% The results for one drug cannot be true. Select the one. 13